8-K: Co-Diagnostics Secures NASDAQ Extension Amidst Minimum Bid Price Non-Compliance

Co-Diagnostics, Inc. has been granted an additional 180-day grace period by NASDAQ until January 5, 2026, to regain compliance with the $1.00 minimum bid price requirement, following its failure to meet the initial compliance deadline.

Summary

• Co-Diagnostics, Inc. received notification from NASDAQ on July 10, 2025, indicating non-compliance with the $1.00 minimum bid price requirement.
• The company did not regain compliance during its initial 180-day grace period.
• NASDAQ has granted an additional 180-day grace period, extending the compliance deadline to January 5, 2026.
• Co-Diagnostics is eligible for this extension as it meets other continued listing requirements, including the market value of publicly held shares.
• The company has provided written notice of its intention to cure the deficiency, potentially by effecting a reverse stock split, if necessary.

Sentiment

Score: 4

Explanation: The company failed to meet the initial NASDAQ compliance deadline for its minimum bid price, which is a negative. However, it has been granted an additional grace period and has a plan to regain compliance, which mitigates the immediate risk of delisting.

Positives

• Received an additional 180-day grace period from NASDAQ, extending the deadline to January 5, 2026, to regain compliance with the minimum bid price requirement.
• Meets the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, except for the bid price.
• Has a stated intention to cure the deficiency, including the potential use of a reverse stock split.

Negatives

• Failed to regain compliance with the NASDAQ $1.00 minimum bid price requirement during the initial 180-day grace period.
• Continues to be non-compliant with a key NASDAQ listing requirement.

Risks

• Potential delisting from The Nasdaq Capital Market if the company fails to regain compliance with the $1.00 minimum bid price requirement by January 5, 2026.
• Risk of a reverse stock split, which can sometimes be perceived negatively by investors and may not guarantee long-term price stability.

Future Outlook

Co-Diagnostics, Inc. intends to cure the deficiency during the second compliance period by potentially effecting a reverse stock split, if necessary, to regain compliance with NASDAQ's $1.00 minimum bid requirement by January 5, 2026.

Management Comments

• Co-Diagnostics, Inc. has provided written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.

Industry Context

This announcement is specific to Co-Diagnostics, Inc.'s listing status and does not directly reflect broader industry trends. However, companies, especially smaller ones, can sometimes face challenges maintaining stock prices above minimum listing requirements due to market volatility or specific company performance issues.

Comparison to Industry Standards

• This is a regulatory compliance issue specific to NASDAQ listing rules and is not directly comparable to financial or operational performance metrics of industry peers.

Corporate Governance

Stakeholder Impact

• Shareholders face potential risks of delisting, which could reduce liquidity and investor confidence. A reverse stock split, if implemented, would reduce the number of outstanding shares and increase the per-share price, but does not change the overall market capitalization.

Next Steps

• Regain compliance with NASDAQ's $1.00 minimum bid requirement by January 5, 2026.
• Potentially effect a reverse stock split to cure the bid price deficiency.

Key Dates

Keywords

Co-Diagnostics, NASDAQ, minimum bid price, compliance, delisting, reverse stock split, 8-K filing